丰明乾，博士、教授、博导

教育经历：

1993.9-1997.7 西北农林科技大学，植物遗传育种，本科

1997.9-2000.7 西北农林科技大学，生物化学与分子生物学理学，硕士

2005.9-2008.7 南京大学，生物学，博士

工作经历:

2000.7-2005.9 华中农业大学生命科学技术学院，讲师

2008.10-2013.11 美国NIH，博士后

2013.11-2015.12，美国NIH，助理研究员

2015.12-至今，华中农业大学，教授

研究方向：

1. 抗体工程与肿瘤免疫治疗研究，包括抗体类药物和CAR-T等细胞免疫治疗技术。

2. 血液性疾病的免疫治疗研究，如EBV感染及EBV相关淋巴增殖性疾病免疫治疗（PTLD、淋巴瘤、嗜血综合症）。

3. 急性肝衰竭与生物人工肝治疗性研究。

代表性论文：

1. Dianbao Zuo, Yuankui Zhu, Ke Wang, Youjia Qin, Yiyi Su, Sina Lan, Yunyi Li, Shuang Dong, Yinming Liang*, Mingqian Feng*. A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding. Biomedicine & Pharmacotherapy. 2024; 175:116782.

2. Yuankui Zhu, Ke Wang, Linghe Yue, Dianbao Zuo, Junfeng Sheng, Sina Lan, Zilong Zhao, Shuang Dong, Sheng Hu^*, Chen Xin^*, Mingqian Feng^*. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects. Pharmacological Research. 2024; 203:107186.

3. Huixia He, Feifei Lei, Le Huang, Ke Wang, Yaxi Yang, Liu Chen, Yun Peng, Yinming Liang, Huabing Tan^*, Xiaoyan Wu^*, Mingqian Feng^*. Immunotherapy of Epstein-Barr virus (EBV) infection and EBV-associated hematological diseases with gp350/CD89-targeted bispecific antibody. Biomedicine & Pharmacotherapy. 2023; 163:114797.

4. Le Huang, Huixia He, Ke Wang, Xuqian Ma, Xin Chen, Wenxin Chen, Xuan Wang, Xiaobing Jiang*, Mingqian Feng*. EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma. Biomedicine & Pharmacotherapy. 2022; 155:113659.

5. Jingwen Li, Lanxin Xiang, Qian Wang, Xuqian Ma, Xin Chen, Yuankui Zhu, Yaxi Yang, Le Huang, Huixia He, Lilei Xu, Xinjun Liang, Shuang Dong, Sheng Hu, Hanjie Li, Mingqian Feng*. Highly potent immunotoxins targeting the N-lobe of GPC3 for immunotherapy of hepatocellular carcinoma. Journal of Cancer. 2022; 13:1370-1384.

6. Xin Chen, Yanmin Chen, Rong Liang, Lanxin Xiang, Jingwen Li, Yuankui Zhu, Huixia He, Le Huang, Dianbao Zuo, Weihang Li, Xinjun Liang, Shuang Dong, Sheng Hu, Mitchell Ho*, Mingqian Feng*. Combination therapy of hepatocellular carcinoma by GPC3-targeted bispecific antibody and Irinotecan is potent in suppressing tumor growth in mice. Molecular Cancer Therapeutics. 2022; 21:149-158.

7. Xin Chen, Norhan Amar, Yuankui Zhu, Chunguang Wang, Chunjiao Xia, Xiaoqing Yang, Dongde Wu, Mingqian Feng*. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. Journal for ImmunoTherapy of Cancer. 2020; 8:e000785

8. Feng M, Gao W, Wang R, Chen W, Man Y, Fig WD, Wang X, Dimitrov DS, and Ho M. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. PNAS, 2013; 110: E1083-91.

授权专利：

1. Mitchell Ho, Mingqian Feng, Wei Gao, Hungnam Kim, and Dimiter S. Dimitrov. Human monoclonal antibodies specific for glypican-3 and use thereof. PCT/US2012/034186（美国专利）;

2. Mitchell Ho, Mingqian Feng, Martin Flajnik. Variable new antigen region receptor (VNAR) antibodies and antibody conjugates targeting tumor and viral antigens. WO2017196847A1（美国专利）;

3. Mitchell Ho, Ira Pastan, Dimiter S. Dimitrov, Zhewei Tang, Mingqian Feng, and Wei Gao. Mesothelin antibodies and methods for eliciting potent antitumor activity. PCT/US2013/059883（美国专利）;

4. 丰明乾，陈鑫。可分泌性表达免疫毒素的嵌合抗原受体修饰的免疫细胞。CN113493772A；

5. 丰明乾，何慧侠。一种EB病毒的中和性抗体及其应用。CN202111646561.5；

科研项目：

主持国家自然科学基金、湖北省基金、武汉市基金等、横向课题项目等10余项。

学术兼职：

美国肿瘤学会（AACR）会员；美国抗体工程学会会员；湖北省免疫学会肿瘤生物治疗专业委员会常务委员。

研究生招生方向：

学硕：肿瘤生物学；生物工程；

专硕：生物与医药（生物技术与产品创制方向）；

讲授课程：

《免疫学》

联系方式：

Fengmingqian@mail.hzau.edu.cn